ПАТОГЕНЕЗ ПОРУШЕНЬ МОРФОФУНКЦІОНАЛЬНОГО СТАНУ ПЕЧІНКИ ПРИ ЦУКРОВОМУ ДІАБЕТІ ПЕРШОГО ТИПУ
DOI:
https://doi.org/10.24061/1727-4338.XIX.2.72.2020.14Ключові слова:
цукровий діабет, гепатопатії, патогенезАнотація
Мета роботи – проаналізувати сучасні наукові погляди на патогенез ушкодженняпечінки при цукровому діабеті першого типу.
Висновок. Проаналізовані літературні дані розкривають механізми порушень
сигнальних шляхів інсуліну при ЦД типу 1, які призводять до активації
гепатотоксичних механізмів.
Посилання
1. Savych OA. Kompleksna radionuklidna diahnostyka
funktsional'noho stanu pechinky ta zhovchnoho mikhura u
khvorykh na tsukrovyi diabet [Comprehensive radionuclide
diagnosis of the functional state of the liver and gallbladder in
patients with diabetes] [dissertation]. Kiev; 2007. 126 p. (in
Ukrainian)
2. Al-Hussaini AA, Sulaiman NM, Alzahrani MD, Alenizi AS, Khan
M. Prevalence of hepatopathy in type 1 diabetic children. BMC
Pediatr [Internet]. 2012[cited 2020 Jul 12];12:160. Available
from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506494/
pdf/1471-2431-12-160.pdf doi: 10.1186/1471-2431-12-160
3. Cusi K, Sanyal AJ, Zhang S, Hartman ML, Bue-Valleskey JM, Hoogwerf BJ, et al. Non-alcoholic fatty liver disease (NAFLD)
prevalence and its metabolic associations in patients with
type 1 diabetes and type 2 diabetes. Diabetes Obes Metab.
2017;19(11):1630-4. doi: 10.1111/dom.12973
4. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old
questions and new insights. Science. 2011;332(6037):1519-23.
doi: 10.1126/science.1204265
5. Llauradó G, Sevastianova K, Sädevirta S, Hakkarainen A,
Lundbom N, Orho-Melander M, et al. Liver fat content and
hepatic insulin sensitivity in overweight patients with type 1
diabetes. J Clin Endocrinol Metab. 2015;100(2):607-16. doi:
10.1210/jc.2014-3050
6. Masaron M, Rosato V, Dallio M, Gravina AG, Aglitti A,
Loguercio C, et al. Role of Oxidative Stress in Pathophysiology
of Nonalcoholic Fatty Liver Disease. Oxid Med Cell Longev
[Internet]. 2018[cited 2020 Jul 12];2018:9547613. Available
from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016172/
pdf/OMCL2018-9547613.pdf doi: 10.1155/2018/9547613
7. Lee JY, Kim MY, Shin SH, Shin MR, Kwon OJ, Kim TH, et
al. Persicarin isolated from Oenanthe javanica protects against
diabetes-induced oxidative stress and inflammation in the liver
of streptozotocin-induced type 1 diabetic mice. Exp Ther Med.
2017;13(4):1194-202. doi: 10.3892/etm.2017.4113
8. Mendes-Braz M, Martins JO. Diabetes Mellitus and Liver
Surgery: The Effect of Diabetes on Oxidative Stress and
Inflammation. Mediators Inflamm [Internet]. 2018[cited 2020 Jul
12];2018:2456579. Available from: https://www.ncbi.nlm.nih.
gov/pmc/articles/PMC5964489/pdf/MI2018-2456579.pdf doi:
10.1155/2018/2456579
9. Magee N, Zou A, Zhang Y. Pathogenesis of Nonalcoholic
Steatohepatitis: Interactions between Liver Parenchymal and
Nonparenchymal Cells. Biomed Res Int [Internet]. 2016[cited
2020 Jul 12];2016:5170402. Available from: https://www.
ncbi.nlm.nih.gov/pmc/articles/PMC5086374/pdf/BMRI2016-
5170402.pdf doi: 10.1155/2016/5170402
10. Bessone F, Razori MV, Roma MG. Molecular pathways of
nonalcoholic fatty liver disease development and progression.
Cell Mol Life Sci. 2019;76(1):99-128. doi: 10.1007/s00018-018-
2947-0
11. Santos JC, Valentim IB, de Araújo OR, Ataide Tda R, Goulart
MO. Development of Nonalcoholic Hepatopathy: Contributions
of Oxidative Stress and Advanced Glycation End Products. Int
J Mol Sci. 2013;14(10):19846–66. doi: 10.3390/ijms141019846
12. Palsamy P, Sivakumar S, Subramanian S. Resveratrol attenuates
hyperglycemia-mediated oxidative stress, proinflammatory
cytokines and protects hepatocytes ultrastructure in streptozotocinnicotinamide-induced experimental diabetic rats. Chem Biol
Interact. 2010;186(2):200–10. doi: 10.1016/j.cbi.2010.03.028
13. Martínez-Flórez S, Gutiérrez-Fernández B, Sánchez-Campos
S, González-Gallego J, Tuñón MJ. Quercetin attenuates nuclear
factor-kappaB activation and nitric oxide production in interleukin-
1beta-activated rat hepatocytes. J Nutr. 2005;135(6):1359–65.
doi: https://doi.org/10.1093/jn/135.6.1359
14. Manna P, Das J, Ghosh J, Sil PC. Contribution of type 1 diabetes
to rat liver dysfunction and cellular damage via activation
of NOS, PARP, IkappaBalpha/NF-kappaB, MAPKs, and
mitochondria-dependent pathways: Prophylactic role of arjunolic
acid. Free Radic Biol Med. 2010;48(11):1465–84. doi: https://doi.
org/10.1016/j.freeradbiomed.2010.02.025
15. Zhang C, Lu X, Tan Y, Li B, Miao X, Jin L, et al. Diabetesinduced hepatic pathogenic damage, inflammation, oxidative
stress, and insulin resistance was exacerbated in zinc deficient
mouse model. PLoS One [Internet]. 2012[cited 2020 Jul
14];7(12):e49257. Available from: https://www.ncbi.nlm.nih.gov/
pmc/articles/PMC3520990/pdf/pone.0049257.pdf doi: 10.1371/
journal.pone.0049257
16. Gu Y, Lian X, Sun W, Gao B, Fu Y. Diabetes Mellitus induces
alterations in metallothionein protein expression and metal levels
in the testis and liver. J Int Med Res. 2018;46(1):185-94. doi:
10.1177/0300060517708923
17. Aldaba-Muruato LR, Moreno MG, Hernández-Mercado E,
Shibayama M, Muriel P. Secondary biliary cirrhosis in the rat is
prevented by decreasing NF-κB nuclear translocation and TGF-β
expression using allopurinol, an inhibitor of xanthine oxidase.
Can J Physiol Pharmacol. 2012;90(11):1469-78. doi: https://doi.
org/10.1139/y2012-125
18. Nakagawa H, Maeda S. Molecular mechanisms of liver injury
and hepatocarcinogenesis: Focusing on the role of stressactivated MAPK. Patholog Res Int [Internet]. 2012[cited 2020
Jul 14];2012:172894. Available from: https://www.ncbi.nlm.nih.
gov/pmc/articles/PMC3361329/pdf/PRI2012-172894.pdf doi:
10.1155/2012/172894
19. Hayes CN, Zhang P, Zhang Y, Chayama K. Molecular Mechanisms
of Hepatocarcinogenesis Following Sustained Virological
Response in Patients with Chronic Hepatitis C Virus Infection.
Viruses [Internet]. 2018[cited 2020 Jul 12];10(10):531. Available
from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212901/
pdf/viruses-10-00531.pdf doi: 10.3390/v10100531
20. Li S, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, et al. The
Role of Oxidative Stress and Antioxidants in Liver Diseases. Int
J Mol Sci. 2015;16(11):26087–124. doi: 10.3390/ijms161125942
21. Zhuang A, Yap FY, Bruce C, Leung C, Plan MR, Sullivan MA, et
al. Increased liver AGEs induce hepatic injury mediated through
an OST48 pathway. Sci Rep [Internet]. 2017[cited 2020 Jul
14];7(1):12292. Available from: https://www.ncbi.nlm.nih.gov/
pmc/articles/PMC5612946/pdf/41598_2017_Article_12548.pdf
doi: 10.1038/s41598-017-12548-4
22. Pereira ENGDS, Silvares RR, Flores EEI, Rodrigues KL, Ramos
IP, da Silva IJ, et al. Hepatic microvascular dysfunction and
increased advanced glycation end products are components of
non-alcoholic fatty liver disease. PLoS One [Internet]. 2017[cited
2020 Jul 11];12(6):e0179654. Available from: https://www.ncbi.
nlm.nih.gov/pmc/articles/PMC5476253/pdf/pone.0179654.pdf
doi: 10.1371/journal.pone.0179654
23. Takeuchi M, Takino J, Sakasai-Sakai A, Takata T, Ueda T,
Tsutsumi M, et al. Involvement of the TAGE-RAGE system in
non-alcoholic steatohepatitis: Novel treatment strategies. World J
Hepatol. 2014;6(12):880-93. doi: 10.4254/wjh.v6.i12.880
24. Hollenbach M. The Role of Glyoxalase-I (Glo-I), Advanced
Glycation Endproducts (AGEs), and Their Receptor (RAGE) in
Chronic Liver Disease and Hepatocellular Carcinoma (HCC).
Int J Mol Sci [Internet]. 2017[cited 2020 Jul 11];18(11):2466.
Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC5713432/pdf/ijms-18-02466.pdf doi: 10.3390/ijms18112466
25. Takeuchi M, Sakasai-Sakai A, Takata T, Ueda T, Takino J,
Tsutsumi M, et al. Serum levels of toxic AGEs (TAGE) may be
a promising novel biomarker in development and progression
of NASH. Med Hypotheses. 2015;84(5):490-3. doi: https://doi.
org/10.1016/j.mehy.2015.02.002
26. Sayej WN, Knight Iii PR, Guo WA, Mullan B, Ohtake PJ, Davidson
BA, et al. Advanced Glycation End Products Induce Obesity
and Hepatosteatosis in CD-1 Wild-Type Mice. Biomed Res Int
[Internet]. 2016[cited 2020 Jul 14];2016:7867852. Available
from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753052/
pdf/BMRI2016-7867852.pdf doi: 10.1155/2016/7867852
27. Guimarães EL, Empsen C, Geerts A, van Grunsven LA.
Advanced glycation end products induce production of reactive
oxygen species via the activation of NADPH oxidase in murine
hepatic stellate cells. J Hepatol. 2010;52(3):389–97. doi: https://
doi.org/10.1016/j.jhep.2009.12.007
28. Iroz A, Couty JP, Postic C. Hepatokines: Unlocking the
multi-organ network in metabolic diseases. Diabetologia.
2015;58(8):1699–703. doi: 10.1007/s00125-015-3634-4
29. Roshanzamir F, Miraghajani M, Rouhani MH, Mansourian M,
Ghiasvand R, Safavi SM. The association between circulating
fetuin-A levels and type 2 diabetes mellitus risk: systematic
review and meta-analysis of observational studies. J Endocrinol
Invest. 2018;41(1):33-47. doi: 10.1007/s40618-017-0697-8
30. 30. Stefan N, Sun Q, Fritsche A, Machann J, Schick F, Gerst
F, et al. Impact of the adipokine adiponectin and the hepatokine
fetuin-A on the development of type 2 diabetes: Prospective
cohort- and cross-sectional phenotyping studies. PLoS One
[Internet]. 2014[cited 2020 Jul 14];9(3):e92238. https://www.
ncbi.nlm.nih.gov/pmc/articles/PMC3958485/pdf/pone.0092238.
pdf doi: 10.1371/journal.pone.0092238
31. Kohl T, Gehrke N, Schad A, Wörns MA, Sprinzl MF, Zimmermann
T, et al. Diabetic liver injury from streptozotocin is regulated
through the caspase-8 homolog cFLIP involving activation of
JNK2 and intrahepatic immunocompetent cells. Cell Death Dis
[Internet]. 2013[cited 2020 Jul 11];4(7):e712. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3730402/pdf/
cddis2013228a.pdf doi: 10.1038/cddis.2013.228
32. Landis J, Shaw LM. Insulin receptor substrate 2-mediated
phosphatidylinositol 3-kinase signaling selectively inhibits
glycogen synthase kinase 3β to regulate aerobic glycolysis. J Biol
Chem. 2014;289(26):18603-13. doi: 10.1074/jbc.M114.564070
33. Mercado-Matos J, Janusis J, Zhu S, Chen SS, Shaw LM.
Identification of a Novel Invasion-Promoting Region in Insulin
Receptor Substrate 2. Mol Cell Biol [Internet]. 2018[cited 2020
Jul 12];38(14):e00590-17. Available from: https://www.ncbi.
nlm.nih.gov/pmc/articles/PMC6024166/pdf/e00590-17.pdf doi:
10.1128/MCB.00590-17
34. Schattenberg JM, Zimmermann T, Wörns M, Sprinzl MF, Kreft
A, Kohl T, et al. Ablation of c-FLIP in hepatocytes enhances
death-receptor mediated apoptosis and toxic liver injury in vivo.
J Hepatol. 2011;55(6):1272-80. doi: 10.1016/j.jhep.2011.03.008
35. Regnell SE, Lernmark A. Hepatic Steatosis in Type 1 Diabetes. Rev
Diabet Stud. 2011;8(4):454–67. doi: 10.1900/RDS.2011.8.454
36. Czech MP, Tencerova M, Pedersen DJ, Aouadi M. Insulin
signalling mechanisms for triacylglycerol storage. Diabetologia.
2013;56(5):949-64. doi: 10.1007/s00125-013-2869-1
37. Kim TH, Kim H, Park JM, Im SS, Bae JS, Kim MY, et
al. Interrelationship between liver X receptor alpha, sterol
regulatory element-binding protein-1c, peroxisome proliferatoractivated receptor gamma, and small heterodimer partner in the
transcriptional regulation of gluco-kinase gene expression in
liver. J Biol Chem. 2009;284(22):15071-83. doi: 10.1074/jbc.
M109.006742
38. Park JM, Kim TH, Jo SH, Kim MY, Ahn YH. Acetylation of
glucokinase regulatory protein decreases glucose metabolism by
suppressing glucokinase activity. Sci Rep [Internet]. 2015[cited
2020 Jul 12];5:17395. Available from: https://www.ncbi.nlm.nih.
gov/pmc/articles/PMC4664969/pdf/srep17395.pdf doi: 10.1038/
srep17395
39. Dentin R, Girard J, Postic C. Carbohydrate responsive element
binding protein (ChREBP) and sterol regulatory element binding
protein-1c (SREBP-1c): two key regulators of glucose metabolism
and lipid synthesis in liver. Biochimie. 2005;87(1):81-6. doi:
10.1016/j.biochi.2004.11.008
40. Takeuchi Y, Yahagi N, Aita Y, Murayama Y, Sawada Y, Piao X,
et al. KLF15 Enables Rapid Switching between Lipogenesis and
Gluconeogenesis during Fasting. Cell Rep. 2016;16(9):2373-86.
doi: 10.1016/j.celrep.2016.07.069
41. Moslehi A, Hamidi-Zad Z. Role of SREBPs in Liver Diseases:
A Mini-review. J Clin Transl Hepatol. 2018;6(3):332-8. doi:
10.14218/JCTH.2017.00061
42. Ferré P, Foufelle F. Hepatic steatosis: a role for de novo lipogenesis
and the transcription factor SREBP-1c. Diabetes Obes Metab.
2010;12(Suppl 2):83-92. doi: 10.1111/j.1463-1326.2010.01275.x
43. Geisler CE, Renquist BJ. Hepatic lipid accumulation: cause
and consequence of dysregulated glucoregulatory hormones. J
Endocrinol [Internet]. 2017[cited 2020 Jul 12];234(1):R1-R21.
Available from: https://joe.bioscientifica.com/view/journals/
joe/234/1/R1.xml doi: 10.1530/JOE-16-0513
44. Softic S, Kirby M, Shroyer N, Kohli R. Hepatic steatosis in type
2 and type 1 diabetes mellitus is mediated by insulin signaling
via fatty acid transport proteins. J Pediatr Gastroenterol Nutr.
2010;51(Suppl 2):E33–4.
45. Fick T, Jack J, Pyle-Eilola AL, Henry RK. Severe
hypertriglyceridemia at new onset type 1 diabetes mellitus. J
Pediatr Endocrinol Metab. 2017;30(8):893-7. doi: 10.1515/jpem-
2017-0008
46. Leung TM, Nieto N. CYP2E1 and oxidant stress in alcoholic and
non-alcoholic fatty liver disease. J Hepatol. 2013;58(2):395–8.
doi: https://doi.org/10.1016/j.jhep.2012.08.018
47. Abaci A, Bekem O, Unuvar T, Ozer E, Bober E, Arslan N, et al.
Hepatic glycogenosis: a rare cause of hepatomegaly in type 1
diabetes mellitus. J Diabetes Complications. 2008;22(5):325–8.
doi: 10.1016/j.jdiacomp.2007.11.002
48. Imtiaz KE, Healy C, Sharif S, Drake I, Awan F, Riley J, et al.
Glycogenic Hepatopathy in Type 1 Diabetes: An Underrecognized.
Diabetes Care [Internet]. 2013[cited 2020 Jul 10];36(1):e6–e7.
Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC3526232/pdf/e6.pdf doi: 10.2337/dc12-1134
49. Atmaca M, Ucler R, Kartal M, Seven I, Alay M, Bayram I, et
al. Glycogenic Hepatopathy in Type 1 Diabetes Mellitus. Case
Reports Hepatol [Internet]. 2015[cited 2020 Jul 10];2015:236143.
Available from: http://downloads.hindawi.com/journals/
crihep/2015/236143.pdf doi: https://doi.org/10.1155/2015/236143
50. Abboud W, Abdulla S, Al Zaabi M, Moufarrej R. Young Man
with Hepatomegaly: A Case of Glycogenic Hepatopathy.
Case Reports Hepatol [Internet]. 2018[cited 2020 Jul
10];2018:6037530. Available from: https://www.ncbi.nlm.nih.
gov/pmc/articles/PMC5925151/pdf/CRIHEP2018-6037530.pdf
doi: 10.1155/2018/6037530
##submission.downloads##
Опубліковано
Номер
Розділ
Ліцензія
Авторське право (c) 2020 O. V. Tkachuk, S. S. Tkachuk, M. A. Povar, S. V. Boshtan, V. D. Sorokhan
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Часопис користується «Типовим шаблоном положення про авторські права».
